Détails du produit
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Human VEGF R2 (Luc) HEK293 Reporter Cell was engineered to not only express NFAT signaling response element, but also express the receptor full length human VEGF R2 (Uniprot: P35968-1). When stimulated with human VEGF protein, the VEGF/VEGF R2 interaction drives NFAT-mediated luminescence. Inhibition of VEGF binding to VEGF R2 by either anti-VEGF or anti-VEGF R2 antibodies results in a decrease in luminescence.
Application
• Screen for anti-human VEGF R2 or anti-human VEGF neutralizing antibody.
• Screen for human VEGF R2 small molecule inhibitor

Growth Properties
Adherent
Selection Marker
Hygromycin B (20 μg/mL) + Puromycin (2 μg/mL)
Complete Growth Medium
DMEM medium + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Receptor Assay

Expression analysis of human VEGF R2 on Human VEGF R2 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human VEGF R2 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-VEGF R2 antibody.Protocol
Application

Inhibition of human VEGF165 protein-induced reporter activity by anti-human VEGF neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human VEGF165 protein (Cat. No. VE5-H4210) with a final concentration of 10 ng/mL. The EC50 of anti-human VEGF neutralizing antibody (Bevacizumab) is approximately 0.071 μg/mL.
Protocol
Inhibition of human VEGF165 protein-induced reporter activity by human VEGF R2 small molecule inhibitor.
This reporter cell was incubated with serial dilutions of inhibitors in the presence of human VEGF165 protein (Cat. No. VE5-H4210) with a final concentration of 10 ng/mL. The EC50 of human VEGF R2 small molecule inhibitor (Cabozantinib) was approximately 0.0053 μM.Protocol
Signaling Bioassay

Response to human VEGF165 protein (RLU).
The Human VEGF R2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (Cat. No. VE5-H4210). The EC50 was approximately 5.13 ng/mL.Protocol
Response to human VEGF165 protein (FOLD).
The Human VEGF R2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (Cat. No. VE5-H4210). The max induction fold was approximately 70.Protocol
Passage Stability

Passage stability analysis by Signaling Bioassay.
The continuously growing Human VEGF R2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (Cat. No. VE5-H4210). Human VEGF165 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-32.Protocol
Avis des utilisateurs Publier un commentaire

Déclaration importante
LIMITED USE AND LICENSE STATEMENT
HEK293 Cell Line Products
By using any HEK293 cell line product purchased from ACRO Biosystems or its affiliates (collectively, "ACROBiosystems"), including the original 293 cells and any modified derivatives thereof (collectively, the "Product"), you (the "Customer") agree to be bound by the following terms of limited use. If you are not willing to accept these terms and the Product remains unused, please contact our customer service at customerservice@acrobiosystems.com to arrange for return of the unused Product for a refund.
1. Scope of Use
For the use of the Product worldwide (excluding Mainland China, Hong Kong, Macao and Taiwan regions), Customer may use the Product for (i) internal research; (ii) drug discovery and assay development; (iii) internal quality assurance testing for biologic drugs and vaccines; and (iv) lot releasing assay for biologic drugs and vaccines, whether conducted by a commercial or non-commercial entity. Unless a separate sublicense has been obtained, it is NOT permitted to use the Product in (i) product manufacturing; (ii) provision of service, information, or data to an unaffiliated third party for a fee; (iii) resale of the Product or its derivatives, whether or not such Product or derivatives are resold for use in research or (iv) other commercial use not expressly permitted above.
For the use of the Product in Greater China region (including Mainland China, Hong Kong, Macao and Taiwan regions), Customer may use the Product for internal research use only. Unless a separate sublicense has been obtained, it is NOT permitted to use the Product for any Commercial Use. For the purpose of this paragraph, "Commercial Use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (i) product manufacture; (ii) provision of service, information or data to a third party for a fee; (iii) resale of the product or its derivatives, whether or not such Product or derivatives are resold for use in research; (iv) quality assurance testing for biologic drugs and vaccines; (v) quality control assays; (vi) lot releasing assay of biologic drugs and vaccines.
If you require a sublicense for any use beyond the limited use permitted herein, including but not limited to commercial use, CRO/service provider activities for a fee, or any product manufacturing activities, please contact the local sales team of ACROBiosystems for further details.
The Product is not intended for any animal or human therapeutic purposes, nor for any direct human in vivo use. The Product shall not be used in or administered to humans.
2. Transfer, Distribution and Sublicensing Restrictions
Unless expressly permitted under a separate written agreement with/via ACROBiosystems, you have NO right to (i) share, transfer, distribute, sell, resell, sublicense, or otherwise make the Product or its derivatives available for use to any third party, including but not limited to other researchers, laboratories, departments, research institutions, hospitals, universities, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), or any other commercial entities; or (ii) use the Product or its derivatives to perform fee-for-service activities or to provide services, information, or data to any third party for monetary or other consideration.
3. Modification and Derivatives
Customers have No right to modify, engineer, genetically alter, or create derivatives of the Product. Any such modification or derivative requires a separate license and additional fees. Please contact our local sales team for further details.
4. No Warranty
ACROBiosystems makes no warranties or representations of any kind, either expressed or implied, with respect to the merchantability, fitness or suitability of the Product for any particular purpose.
5. Limitation of Liability
To the fullest extent permitted by law, in no event shall ACROBiosystems or its licensors be liable for any use by Customer of the Product, any derivative thereof, or any material treated therewith for any losses, costs, claims, damages, or liability of whatsoever kind or nature which may arise from or in connection with the use of the Product.
6. Compliance with Laws
Customer agrees to use the Product in compliance with all applicable laws, regulations, and governmental guidelines applicable to the Product, any derivative thereof, and any materials treated therewith.
ACKNOWLEDGMENT
By using this Product, Customer acknowledges that he/she has read, understood, and agreed to be bound by the terms and conditions of this Limited Use and License Statement. If Customer does not agree to comply with these terms, Customer shall not open or use the Product and shall contact ACROBiosystems to arrange for return of the unused Product.
Progrès de frontière
- Nom anglais:
Vascular endothelial growth factor receptor 2
- Catégorie:
- Nombre de médicaments répertoriés:
18 Détails
- Nombre de médicaments cliniques:
62 Détails
- Étape de développement la plus élevée:
Approved




















